Home LiteratureArticle Details
PMID: 9472642 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

The ubiquitin-proteasome pathway in cancer.

British journal of cancer ·Vol. 77 ·No. 3 ·1998-00-00 ·Pages 448-55

Spataro V, Norbury C, Harris AL

Abstract

Degradation by the 26S proteasome of specific proteins that have been targeted by the ubiquitin pathway is the major intracellular non-lysosomal proteolytic mechanism and is involved in a broad range of processes, such as cell cycle progression, antigen presentation and control of gene expression. Recent work, reviewed here, has shown that this pathway is often the target of cancer-related deregulation and can underlie processes, such as oncogenic transformation, tumour progression, escape from immune surveillance and drug resistance.

MeSH Terms
Animals Antigen Presentation Cell Cycle Proteins Cyclin-Dependent Kinase Inhibitor p27 Cysteine Endopeptidases/metabolism Drug Resistance, Neoplasm Genes, p53/physiology Humans Microfilament Proteins Microtubule-Associated Proteins/analysis Multienzyme Complexes/metabolism Neoplasms/drug therapy,immunology,metabolism Papillomaviridae/genetics Prognosis Proteasome Endopeptidase Complex Transcription Factors/physiology Tumor Suppressor Proteins Ubiquitins/metabolism
Chemicals
Cell Cycle Proteins Microfilament Proteins Microtubule-Associated Proteins Multienzyme Complexes Transcription Factors Tumor Suppressor Proteins Ubiquitins Cyclin-Dependent Kinase Inhibitor p27 Cysteine Endopeptidases Proteasome Endopeptidase Complex
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Spataro V
Imperial Cancer Research Fund, University of Oxford, Institute of Molecular Medicine, The John Radcliffe, UK.
Norbury C
Harris A L
References (100)
100 references, click to expand
  1. Structural features of the 26 S proteasome complex.
    J Mol Biol. 1993 Dec 20;234(4):932-7 PMID: 8263938
  2. Cyclin E, a potential prognostic marker for breast cancer.
    Cancer Res. 1994 Jan 15;54(2):380-5 PMID: 7903908
  3. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest.
    Genes Dev. 1994 Jan;8(1):9-22 PMID: 8288131
  4. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway.
    Mol Cell Biol. 1994 Mar;14(3):1997-2003 PMID: 8114731
  5. Degradation of the tumor suppressor protein p53 by the ubiquitin-mediated proteolytic system requires a novel species of ubiquitin-carrier protein, E2.
    J Biol Chem. 1994 Apr 1;269(13):9582-9 PMID: 8144545
  6. A beta-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line.
    Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3358-62 PMID: 8159752
  7. Ligand-activated platelet-derived growth factor beta-receptor is degraded through proteasome-dependent proteolytic pathway.
    Biochem Biophys Res Commun. 1995 Dec 5;217(1):224-9 PMID: 8526915
  8. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells.
    Biochem Biophys Res Commun. 1995 Dec 26;217(3):1070-7 PMID: 8554559
  9. Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas.
    Hum Genet. 1996 Jan;97(1):91-4 PMID: 8557269
  10. Caffeine-resistance in fission yeast is caused by mutations in a single essential gene, crm1+.
    Mol Gen Genet. 1996 Jan 15;250(1):59-68 PMID: 8569688
  11. Potential for protein kinase C inhibitors in cancer therapy.
    Cancer Treat Res. 1995;78:3-27 PMID: 8595146
  12. Translational control of p27Kip1 accumulation during the cell cycle.
    Science. 1996 Mar 29;271(5257):1861-4 PMID: 8596954
  13. Identification of MECL-1 (LMP-10) as the third IFN-gamma-inducible proteasome subunit.
    J Immunol. 1996 Apr 1;156(7):2361-4 PMID: 8786291
  14. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression.
    Cancer Res. 1996 Apr 15;56(8):1756-60 PMID: 8620489
  15. LMP-associated proteolytic activities and TAP-dependent peptide transport for class 1 MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12.
    J Exp Med. 1996 Feb 1;183(2):499-514 PMID: 8627162
  16. A third interferon-gamma-induced subunit exchange in the 20S proteasome.
    Eur J Immunol. 1996 Apr;26(4):863-9 PMID: 8625980
  17. Ubiquitinylation of transcription factors c-Jun and c-Fos using reconstituted ubiquitinylating enzymes.
    J Biol Chem. 1996 Mar 1;271(9):4930-6 PMID: 8617766
  18. A conditional lethal mutant in the fission yeast 26 S protease subunit mts3+ is defective in metaphase to anaphase transition.
    J Biol Chem. 1996 Mar 8;271(10):5704-11 PMID: 8621436
  19. In vivo ubiquitination and proteasome-mediated degradation of p53(1).
    Cancer Res. 1996 Jun 1;56(11):2649-54 PMID: 8653711
  20. Newly identified pair of proteasomal subunits regulated reciprocally by interferon gamma.
    J Exp Med. 1996 Apr 1;183(4):1807-16 PMID: 8666937
  21. Role of oxidants and antioxidants in the induction of AP-1, NF-kappaB, and glutathione S-transferase gene expression.
    J Biol Chem. 1996 Jun 7;271(23):13422-9 PMID: 8662787
  22. The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome.
    J Biol Chem. 1996 Jul 12;271(28):16455-9 PMID: 8663210
  23. Enhancement of CPP32-like activity in the TNF-treated U937 cells by the proteasome inhibitors.
    Biochem Biophys Res Commun. 1996 Jul 5;224(1):74-9 PMID: 8694836
  24. Proteasome subunits X and Y alter peptidase activities in opposite ways to the interferon-gamma-induced subunits LMP2 and LMP7.
    J Biol Chem. 1996 Jul 19;271(29):17275-80 PMID: 8663318
  25. Apoptosis induction resulting from proteasome inhibition.
    Biochem J. 1996 Jul 15;317 ( Pt 2):385-8 PMID: 8713062
  26. Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons.
    EMBO J. 1996 Aug 1;15(15):3845-52 PMID: 8670889
  27. Cyclin D1, another molecule of the year?
    Ann Oncol. 1996 Mar;7(3):223-5 PMID: 8740783
  28. Differential effects of ubiquitin aldehyde on ubiquitin and ATP-dependent protein degradation.
    Biochemistry. 1996 Aug 20;35(33):10886-93 PMID: 8718881
  29. Ubiquitination of protein kinase C-alpha and degradation by the proteasome.
    J Biol Chem. 1996 Aug 30;271(35):20973-6 PMID: 8702857
  30. Control of gene expression by proteolysis.
    Curr Opin Cell Biol. 1996 Jun;8(3):340-7 PMID: 8743884
  31. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation.
    Genes Dev. 1996 Aug 15;10(16):1979-90 PMID: 8769642
  32. Evidence that a rapidly turning over protein, normally degraded by proteasomes, regulates hsp72 gene transcription in HepG2 cells.
    J Biol Chem. 1996 Oct 4;271(40):24769-75 PMID: 8798747
  33. A new group of conserved coactivators that increase the specificity of AP-1 transcription factors.
    Nature. 1996 Oct 3;383(6599):453-7 PMID: 8837781
  34. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies.
    J Natl Cancer Inst. 1996 Oct 16;88(20):1442-55 PMID: 8841019
  35. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death.
    Science. 1996 Nov 1;274(5288):782-4 PMID: 8864118
  36. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB.
    Science. 1996 Nov 1;274(5288):784-7 PMID: 8864119
  37. Purification and cloning of a nucleotide excision repair complex involving the xeroderma pigmentosum group C protein and a human homologue of yeast RAD23.
    EMBO J. 1994 Apr 15;13(8):1831-43 PMID: 8168482
  38. Activation-dependent ubiquitination of a T cell antigen receptor subunit on multiple intracellular lysines.
    J Biol Chem. 1994 May 13;269(19):14244-7 PMID: 8188707
  39. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells.
    Mol Cell Biol. 1994 Jun;14(6):3683-94 PMID: 8196612
  40. Involvement of Jun and Fos proteins in regulating transcriptional activation of the human pi class glutathione S-transferase gene in multidrug-resistant MCF7 breast cancer cells.
    J Biol Chem. 1994 Jun 10;269(23):16397-402 PMID: 8206948
  41. Closing the cell cycle circle in yeast: G2 cyclin proteolysis initiated at mitosis persists until the activation of G1 cyclins in the next cycle.
    Cell. 1994 Jul 1;77(7):1037-50 PMID: 8020094
  42. Displacement of housekeeping proteasome subunits by MHC-encoded LMPs: a newly discovered mechanism for modulating the multicatalytic proteinase complex.
    EMBO J. 1994 Jul 15;13(14):3236-44 PMID: 8045254
  43. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B.
    Cell. 1994 Sep 9;78(5):773-85 PMID: 8087845
  44. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain.
    Cell. 1994 Sep 9;78(5):787-98 PMID: 8087846
  45. The ubiquitin-proteasome proteolytic pathway.
    Cell. 1994 Oct 7;79(1):13-21 PMID: 7923371
  46. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age.
    Cell. 1994 Nov 18;79(4):573-82 PMID: 7954824
  47. Proteasomes: protein degradation machines of the cell.
    Trends Biochem Sci. 1994 Sep;19(9):377-82 PMID: 7985232
  48. Proteasome components with reciprocal expression to that of the MHC-encoded LMP proteins.
    Curr Biol. 1994 Sep 1;4(9):769-76 PMID: 7820546
  49. Reconstitution of p53-ubiquitinylation reactions from purified components: the role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6AP).
    Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3264-8 PMID: 7724550
  50. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution.
    Science. 1995 Apr 28;268(5210):533-9 PMID: 7725097
  51. Molecular cloning and expression of subunit 12: a non-MCP and non-ATPase subunit of the 26 S protease.
    FEBS Lett. 1995 Apr 17;363(1-2):97-100 PMID: 7729561
  52. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin.
    Science. 1995 May 5;268(5211):726-31 PMID: 7732382
  53. Ubiquitinylation is not an absolute requirement for degradation of c-Jun protein by the 26 S proteasome.
    J Biol Chem. 1995 May 12;270(19):11623-7 PMID: 7744802
  54. cDNA cloning of p40, a regulatory subunit of the human 26S proteasome, and a homolog of the Mov-34 gene product.
    Biochem Biophys Res Commun. 1995 May 16;210(2):600-8 PMID: 7755639
  55. A novel essential fission yeast gene pad1+ positively regulates pap1(+)-dependent transcription and is implicated in the maintenance of chromosome structure.
    J Cell Sci. 1995 Feb;108 ( Pt 2):569-79 PMID: 7769002
  56. Elevated expression of Unph, a proto-oncogene at 3p21.3, in human lung tumors.
    Oncogene. 1995 Jun 1;10(11):2179-83 PMID: 7784062
  57. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation.
    Curr Opin Cell Biol. 1995 Apr;7(2):215-23 PMID: 7612274
  58. Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases.
    J Biol Chem. 1995 Jul 14;270(28):16580-7 PMID: 7622464
  59. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27.
    Science. 1995 Aug 4;269(5224):682-5 PMID: 7624798
  60. Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma.
    Blood. 1995 Sep 1;86(5):1924-30 PMID: 7655021
  61. Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines.
    Cancer Res. 1995 Oct 1;55(19):4367-74 PMID: 7671249
  62. Deregulation of cyclin E in breast cancer.
    Oncogene. 1995 Sep 7;11(5):941-50 PMID: 7675453
  63. The interferon-gamma-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro.
    J Biol Chem. 1995 Oct 6;270(40):23808-15 PMID: 7559557
  64. Degradation of c-Fos by the 26S proteasome is accelerated by c-Jun and multiple protein kinases.
    Mol Cell Biol. 1995 Oct;15(10):5682-7 PMID: 7565719
  65. Incorporation of major histocompatibility complex--encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon-gamma.
    Eur J Immunol. 1995 Sep;25(9):2605-11 PMID: 7589133
  66. Proteolysis. The proteasome: a protein-degrading organelle?
    Curr Biol. 1995 Aug 1;5(8):854-8 PMID: 7583140
  67. LMP2+ proteasomes are required for the presentation of specific antigens to cytotoxic T lymphocytes.
    Curr Biol. 1995 Aug 1;5(8):923-30 PMID: 7583150
  68. Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage.
    Bioessays. 1995 Jun;17(6):501-8 PMID: 7575491
  69. Subunits of the regulatory complex of the 26S protease.
    Mol Biol Rep. 1995;21(1):27-34 PMID: 7565660
  70. Fos is an essential component of the mammalian UV response.
    EMBO J. 1995 Nov 1;14(21):5338-49 PMID: 7489723
  71. Suppression of TNF-alpha-induced apoptosis by NF-kappaB.
    Science. 1996 Nov 1;274(5288):787-9 PMID: 8864120
  72. The proteolysis of mitotic cyclins in mammalian cells persists from the end of mitosis until the onset of S phase.
    EMBO J. 1996 Oct 1;15(19):5280-9 PMID: 8895573
  73. How proteolysis drives the cell cycle.
    Science. 1996 Dec 6;274(5293):1652-9 PMID: 8939846
  74. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas.
    Nat Med. 1997 Feb;3(2):231-4 PMID: 9018245
  75. The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells.
    Eur J Immunol. 1997 Jan;27(1):336-41 PMID: 9022037
  76. Incubation at the nonpermissive temperature induces deficiencies in UV resistance and mutagenesis in mouse mutant cells expressing a temperature-sensitive ubiquitin-activating enzyme (E1).
    Mol Cell Biol. 1997 Mar;17(3):1484-9 PMID: 9032276
  77. Editing of ubiquitin conjugates by an isopeptidase in the 26S proteasome.
    Nature. 1997 Feb 20;385(6618):737-40 PMID: 9034192
  78. The human homologue of yeast CRM1 is in a dynamic subcomplex with CAN/Nup214 and a novel nuclear pore component Nup88.
    EMBO J. 1997 Feb 17;16(4):807-16 PMID: 9049309
  79. Structure of 20S proteasome from yeast at 2.4 A resolution.
    Nature. 1997 Apr 3;386(6624):463-71 PMID: 9087403
  80. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway.
    Genes Dev. 1997 Apr 15;11(8):957-72 PMID: 9136925
  81. Mdm2 promotes the rapid degradation of p53.
    Nature. 1997 May 15;387(6630):296-9 PMID: 9153395
  82. MHC class I expression in mice lacking the proteasome subunit LMP-7.
    Science. 1994 Aug 26;265(5176):1234-7 PMID: 8066463
  83. Increased c-jun/AP-1 levels in etoposide-resistant human leukemia K562 cells.
    Biochem Pharmacol. 1994 Aug 3;48(3):525-33 PMID: 8068039
  84. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules.
    Cell. 1994 Sep 9;78(5):761-71 PMID: 8087844
  85. Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases.
    Science. 1997 Jan 17;275(5298):400-2 PMID: 8994040
  86. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients.
    Nat Med. 1997 Feb;3(2):222-5 PMID: 9018243
  87. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer.
    Nat Med. 1997 Feb;3(2):227-30 PMID: 9018244
  88. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.
    Cell. 1990 Dec 21;63(6):1129-36 PMID: 2175676
  89. Cyclin is degraded by the ubiquitin pathway.
    Nature. 1991 Jan 10;349(6305):132-8 PMID: 1846030
  90. Response of human breast cancer cells to heat shock and chemotherapeutic drugs.
    Cancer Res. 1992 Jul 1;52(13):3648-54 PMID: 1617638
  91. Fission yeast pap1-dependent transcription is negatively regulated by an essential nuclear protein, crm1.
    Mol Cell Biol. 1992 Dec;12(12):5474-84 PMID: 1448080
  92. DNA sequence analysis of 66 kb of the human MHC class II region encoding a cluster of genes for antigen processing.
    J Mol Biol. 1992 Nov 20;228(2):433-41 PMID: 1453454
  93. Identification of human cancers deficient in antigen processing.
    J Exp Med. 1993 Feb 1;177(2):265-72 PMID: 8426105
  94. Redundant cyclin overexpression and gene amplification in breast cancer cells.
    Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1112-6 PMID: 8430082
  95. Translocation t(6;9)(p23;q34) in acute myeloid leukemia without myelodysplasia or basophilia: two cases and a review of the literature.
    Leukemia. 1993 Apr;7(4):527-31 PMID: 8464230
  96. A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation.
    Nature. 1993 Jun 10;363(6429):552-4 PMID: 8389422
  97. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53.
    Cell. 1993 Nov 5;75(3):495-505 PMID: 8221889
  98. The Saccharomyces cerevisiae DNA repair gene RAD23 encodes a nuclear protein containing a ubiquitin-like domain required for biological function.
    Mol Cell Biol. 1993 Dec;13(12):7757-65 PMID: 8246991
  99. The yeast DOA4 gene encodes a deubiquitinating enzyme related to a product of the human tre-2 oncogene.
    Nature. 1993 Nov 25;366(6453):313-9 PMID: 8247125
  100. Defective mitosis due to a mutation in the gene for a fission yeast 26S protease subunit.
    Nature. 1993 Nov 25;366(6453):355-7 PMID: 8247131
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
0007-0920
DOI
10.1038/bjc.1998.71
Published
1998-00-00
Pages
448-55
Language
English
Region
England
NLM ID
0370635
PMCID
PMC2151296
Subset
IM
External Links
PubMed source DOI: 10.1038/bjc.1998.71 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2